Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Residency, University Of Wisconsin-Madison
1979
Doctor of Philosophy, University Of Wisconsin-Madison
1975
Internship, University Of Wisconsin-Madison
1975
Doctor of Medicine, University Of Wisconsin-Madison
1974
Fingerprint
Dive into the research topics where Edward Kasarskis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
-
TO 11: RSA F: ABBV-CLS-7262
Kasarskis, E. (PI)
Massachusetts General Hospital
3/8/23 → 3/7/26
Project: Research project
-
WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Mathur Kumaraswamy, V. (PI) & Kasarskis, E. (CoI)
Woolsey Pharmaceuticals Incorporated
4/25/22 → 2/19/26
Project: Research project
-
Task Order 1: Platform Level Site Support for Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis
Kasarskis, E. (PI)
Massachusetts General Hospital
2/4/20 → 2/22/26
Project: Research project
-
HEALEY ALS Platform Trial: Start-Up
Kasarskis, E. (PI)
Massachusetts General Hospital
1/17/20 → 1/17/26
Project: Research project
-
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis
the Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group, Jan 2025, In: Muscle and Nerve. 71, 1, p. 63-72 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
HEALEY ALS Platform Trial Study Group, Feb 3 2025, In: JAMA network open. 8, 2, p. e2459058Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis
Lee, I., Mitsumoto, H., Lee, S., Kasarskis, E., Rosenbaum, M., Factor-Litvak, P. & Nieves, J. W., Mar 2025, In: Annals of Clinical and Translational Neurology. 12, 3, p. 491-498 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A brief report on juvenile amyotrophic lateral sclerosis cases in the United States National ALS Registry: 2010–2018
Raymond, J., Berry, J., Kasarskis, E. J., Larson, T., Horton, D. K. & Mehta, P., 2024, In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25, 1-2, p. 211-213 3 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Higher Glycemic Index and Glycemic Load Diet Is Associated with Slower Disease Progression in Amyotrophic Lateral Sclerosis
Lee, I., Mitsumoto, H., Lee, S., Kasarskis, E., Rosenbaum, M., Factor-Litvak, P. & Nieves, J. W., Feb 2024, In: Annals of Neurology. 95, 2, p. 217-229 13 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations